(Q38196701)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638138%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

review article

1 reference

title

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638138%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

0 references

1 reference

Benjamin Schattling

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638138%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

language of work or name

English

0 references

publication date

18 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638138%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

published in

Nature Reviews Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638138%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638138%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638138%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

225-238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638138%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrneurol.2014.37

10 March 2020

exact match

0 references

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Oligodendroglia metabolically support axons and contribute to neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

The contribution of demyelination to axonal loss in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Therapies for multiple sclerosis: translational achievements and outstanding needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Pathology of demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Inflammatory cortical demyelination in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Widespread demyelination in the cerebellar cortex in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Casting light on multiple sclerosis heterogeneity: the role of HLA-DRB1 on spinal cord pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Risk alleles for multiple sclerosis identified by a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

MGAT5 alters the severity of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Genome-wide association study of severity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

The value of animal models for drug development in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Oxidative damage in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Disease-specific molecular events in cortical multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Iron and neurodegeneration in the multiple sclerosis brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Ceruloplasmin protects injured spinal cord from iron-mediated oxidative damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Progressive multiple sclerosis: pathology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Susceptibility-weighted imaging in the experimental autoimmune encephalomyelitis model of multiple sclerosis indicates elevated deoxyhemoglobin, iron deposition and demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Redox regulation of cellular stress response in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Mitochondrial energetics and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Premature ageing in mice expressing defective mitochondrial DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

POLG1 variations presenting as multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Oral resveratrol reduces neuronal damage in a model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Updated energy budgets for neural computation in the neocortex and cerebellum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Energy-efficient action potentials in hippocampal mossy fibers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Sodium entry during action potentials of mammalian neurons: incomplete inactivation and reduced metabolic efficiency in fast-spiking neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

The optimum density of sodium channels in an unmyelinated nerve

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Loss of Na+ channel beta2 subunits is neuroprotective in a mouse model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Axonal protection using flecainide in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Transient receptor potential channels as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Physiological roles of the TRPM4 channel extracted from background currents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

K+ channel alterations in the progression of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Block of neural Kv1.1 potassium channels for neuroinflammatory disease therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Molecular dissection of the myelinated axon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Role of n-type voltage-dependent calcium channels in autoimmune optic neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Mechanisms of axonal injury: internodal nanocomplexes and calcium deregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Mitochondrial changes within axons in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Glutamate receptor expression in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Acid-sensing ion channels in pain and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Extracellular acidosis increases neuronal cell calcium by activating acid-sensing ion channel 1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Mice overexpressing Bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

NMDA receptor pathways as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Mitochondrial defects in acute multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Population genetic study of the brain-derived neurotrophic factor (BDNF) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Potential therapeutic uses of BDNF in neurological and psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

CB1 cannabinoid receptors and on-demand defense against excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Beneficial effect of erythropoietin on experimental allergic encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Onset of secondary progressive phase and long-term evolution of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Relapses and progression of disability in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Grey Matter Pathology in Multiple Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Distinct role of nitric oxide and peroxynitrite in mediating oligodendrocyte toxicity in culture and in experimental autoimmune encephalomyelitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Electrically active axons degenerate when exposed to nitric oxide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Axonal protection achieved in a model of multiple sclerosis using lamotrigine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Altered Glutamate Reuptake in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Cortex: Correlation With Microglia Infiltration, Demyelination, and Neuronal and Synaptic Damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Glutamate metabolism is down-regulated in astrocytes during experimental allergic encephalomyelitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Glutamate excitotoxicity in a model of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Autoimmune encephalomyelitis ameliorated by AMPA antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Recruiting adaptive cellular stress responses for successful brain ageing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.37

Therapeutic potential of neuronal two-pore domain potassium-channel modulators

31 March 2020

1 reference

12 December 2020

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Iron deposits surrounding multiple sclerosis plaques.

1 reference

12 December 2020

Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis.

1 reference

12 December 2020

Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult

1 reference

12 December 2020